Healthcare ❯ Pharmaceuticals ❯ Weight Loss Drugs ❯ GLP-1 Medications
Intensified competition from Eli Lilly's Zepbound and compounded semaglutide products has led to flat prescriptions, underwhelming trial results, and a 25% share drop in March 2025.
